Cyprotex Highlights - July 2020
Learn more about our 3D neurotoxicity assay which uses brain microtissues combined with high content imaging to accurately predict neurotoxicity.
The model offers improved longevity and better recapitulation of in vivo cellular physiology compared to traditional 2D systems.
Throughout September, Cyprotex is hosting its first webinar series focused on the area of drug transporters.
Each Wednesday in September, a different speaker will be presenting on their latest research in this field. We have a great line up of speakers from Novartis, Genentech and Cyprotex.
Read our latest publication co-authored with our colleagues in the EU-ToxRisk consortium.
The article, published in Archives of Toxicology, is entitled: ‘Multiparametric assessment of mitochondrial respiratory inhibition in HepG2 and RPTEC/TERT1 cells using a panel of mitochondrial targeting agrochemicals’.
It details a systematic approach to assessing the suitability of a range of different assay types with the intent to formulate a consensus driven mitochondrial toxicity testing platform.
Read the latest news from parent company, Evotec:
- Evotec publishes DDup 9 on iPSC-based retinal disease drug discovery
- Evotec expands its Toulouse-based operations with 'Campus Curie'
- Evotec forms partnership with QUANTRO Therapeutics
- Just - Evotec Biologics to develop and manufacture monoclonal antibodies against COVID-19 for the US Department of Defense
- New webinar: Target discovery for colon and lung cancer through multiomics analysis of high quality patient samples
Telephone:
Europe: +44 (0)1625 505100
North America (East Coast): +1-888-297-7683
Email:
enquiries@cyprotex.com